• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David C. Harmon, MD


  • Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD.
    Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Cancer. 2015 Apr 15;121(8):1223-30.
  • Delaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, Depauw N, Nielsen GP, Harmon DC, Yoon SS, Chen YL, Schwab JH, Hornicek FJ.
    Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas.
    J Surg Oncol. 2014 Apr 19.
  • Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, Szymonifka J, Yeap BY, Chen YL, Harmon DC, Choy E, Yoon SS, Raskin KA, Hornicek FJ, Nielsen GP.
    β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Oncologist. 2013;18(9):1043-9.
  • Garrett LA, Harmon DC, Schorge JO.
    Embryonal rhabdomyosarcoma of the uterine corpus.
    J Clin Oncol. 2013 Feb 1;31(4):e48-50.
  • Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z.
    Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1.
    J Neurosurg. 2012 Oct 26.
  • Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS, Nielsen GP, Szymonifka J, Yeap BY, Delaney TF, Mullen JT.
    Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study.
    Eur J Cancer. 2012 Oct 20.
  • Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, Rosenberg AE, Harmon DC, Choy E, Yoon SS, Raskin KA, Petur Nielsen G, Hornicek FJ.
    Desmoid Tumor: Analysis of Prognostic Factors and Outcomes in a Surgical Series.
    Ann Surg Oncol. 2012 Sep 11.
  • Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, Sassi S, Yang S, Harmon DC, Yang C, Schwab JH, Kobayashi E, Mankin HJ, Xavier R, Weissleder R, Duan Z, Hornicek FJ.
    Establishment and characterization of a novel chordoma cell line: CH22.
    J Orthop Res. 2012 Oct;30(10):1666-73.
  • Look Hong NJ, Pandalai PK, Hornick JL, Shekar PS, Harmon DC, Chen YL, Butrynski JE, Baldini EH, Raut CP.
    Cardiac angiosarcoma management and outcomes: 20-year single-institution experience.
    Ann Surg Oncol. 2012 Aug;19(8):2707-15.
  • Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Ebb DH, Choy E, Raskin KA, Liebsch N, Hornicek FJ, Delaney TF.
    Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.
    Cancer. 2011 Mar 29.
  • Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF.
    Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas.
    Int J Radiat Oncol Biol Phys. 2010 Oct 5.
  • Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B.
    Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    Cancer. 2010 Oct 1;116(19):4613-21.
  • Yoon SS, Chen YL, Kirsch DG, Maduekwe UN, Rosenberg AE, Nielsen GP, Sahani DV, Choy E, Harmon DC, Delaney TF.
    Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas.
    Ann Surg Oncol. 2010 Jun;17(6):1515-29.
  • Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ.
    Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
    Mol Cancer Ther. 2009 Aug;8(8):2122-30.
  • George S,Merriam P,Maki RG,Van den Abbeele AD,Yap JT,Akhurst T,Harmon DC,Bhuchar G,O'Mara MM,D'Adamo DR,Morgan J,Schwartz GK,Wagner AJ,Butrynski JE,Demetri GD,Keohan ML.
    Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas.
    J Clin Oncol. 2009 Jul 1;27(19):3154-60.
  • Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, Iafrate J, Delaney T, Yoon S, Choy E, Harmon D, Raskin K, Yang C, Mankin H, Springfield D, Hornicek F, Duan Z.
    Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
    Anticancer Res. 2009 Jun;29(6):1867-71.
  • Maduekwe UN,Hornicek FJ,Springfield DS,Raskin KA,Harmon DC,Choy E,Rosenberg AE,Nielsen GP,DeLaney TF,Chen YL,Ott MJ,Yoon SS.
    Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas.
    Ann Surg Oncol. 2009 May;16(5):1356-63.
  • DeLaney TF,Liebsch NJ,Pedlow FX,Adams J,Dean S,Yeap BY,McManus P,Rosenberg AE,Nielsen GP,Harmon DC,Spiro IJ,Raskin KA,Suit HD,Yoon SS,Hornicek FJ.
    Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas.
    Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):732-9.
  • Laghari ZA, Harmon D.
    Ultrasound-guided transabdominus plane block.
    J Clin Anesth. 2008 Mar;20(2):156-8.
  • Harmon D, Hearty C.
    In response to letter to the editor (diameter of suprascapular nerve in the suprascapular notch).
    Pain Physician. 2008 Mar;11(2):264.
  • Liao SF, Alman MJ, Vanzant ES, Miles ED, Harmon DL, McLeod KR, Boling JA, Matthews JC.
    Basal expression of nucleoside transporter mRNA differs among small intestinal epithelia of beef steers and is differentially altered by ruminal or abomasal infusion of starch hydrolysate.
    J Dairy Sci. 2008 Apr;91(4):1570-84.
  • Ghori K, Harmon D, Lan W, Seigne P, Walsh F, Shorten GD.
    The effect of midazolam on cerebral endothelial (P-selectin and ICAM-1) adhesion molecule expression during hypoxia-reperfusion injury in vitro.
    Eur J Anaesthesiol. 2008 Mar;25(3):206-10.
  • Harmon D, Hearty C.
    Ultrasound-guided suprascapular nerve block technique.
    Pain Physician. 2007 Nov;10(6):743-6.
  • Atkinson RL, Toone CD, Robinson TJ, Harmon DL, Ludden PA.
    Effects of supplemental ruminally degradable protein versus increasing amounts of supplemental ruminally undegradable protein on nitrogen retention, apparent digestibility, and nutrient flux across visceral tissues in lambs fed low-quality forage.
    J Anim Sci. 2007 Dec;85(12):3331-9.
  • Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML.
    Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
    J Clin Oncol. 2007 Jul 1;25(19):2755-63.
  • Merrill ML, Bohnert DW, Harmon DL, Craig AM, Schrick FN.
    The ability of a yeast-derived cell wall preparation to minimize the toxic effects of high-ergot alkaloid tall fescue straw in beef cattle.
    J Anim Sci. 2007 Oct;85(10):2596-605.
  • Hu P, Harmon D, Frizelle H.
    Ultrasound guidance for ilioinguinal/iliohypogastric nerve block: a pilot study.
    Ir J Med Sci. 2007 Jul-Sep;176(2):111-5.
  • Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, Delaney TF, Yoon SS.
    Treatment and Outcome of 82 Patients with Angiosarcoma.
    Ann Surg Oncol. 2007 Jun;14(6):1953-67.
  • Ghori KA, Harmon DC, Elashaal A, Butler M, Walsh F, O'Sullivan MG, Shorten GD.
    Effect of midazolam versus propofol sedation on markers of neurological injury and outcome after isolated severe head injury: a pilot study.
    Crit Care Resusc. 2007 Jun;9(2):166-71.
  • Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.
    Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Clin Cancer Res. 2004 Sep 1;10(17):5732-40.
  • Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD.
    Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
    J Clin Oncol. 2004 Apr 15;22(8):1480-90.
  • Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D.
    Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
    Cancer. 2003 Aug 15;98(4):832-40.
  • DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC.
    Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
    Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27.
  • Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG.
    Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
    Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19.